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Abstract: A potential strategy for drug lead identification and in-active natural products re-discovery is elaborated. Starting from 
fifteen structurally diverse natural products, a focused library featured by Michael acceptors is constructed with IBX mediated  
oxidation. Biological assay on five tumor cell lines indicates that four Michael acceptors, 8a, 11a, 12a, 14a, are with improved  
cytotoxicity (3–10 folds more potent than the parent compounds), which merit further investigations. Further thiol-sensitive assay 
of the active hit 8a revealed that it was an irreversible Michael acceptor. The results suggest that the strategy is not only effective 
and relatively high discovery rate (28%), but also resource saving. 
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Introduction 
Drug-lead identification is the first step of drug discovery. 
A good start may set a success keynote for the whole process. 
So it is worthwhile to pay more attention on drug lead 
identification. Though plenty methods, including random 
screening, high-throughput screening from database, fragment 
based lead design and computer aided lead identification, are 
available for drug lead discovery1,2, some challenges remain 
un-addressed. The discovery efficiency and structure diversity 
are often low, and the leads are always hampered on the way 
to drug candidates. In one word, the lead quality is frequently 
unsatisfactory3,4. 
On the other hand, the abundant structure and function 
diversity fueled by natural products has provided a steady flow 
for the novel drugs. Many drugs used in clinic are natural 
products or compounds derived from natural products5–7. It is 
particularly true in anti-cancer and anti-infectious therapy field. 
We would like to dig out something valuable from this under-
estimated repository. 
What’s more, in the drug lead identification process, the 
major attentions are focused on the active hits, leaving vast 
amount of counterparts under-valued. And what shocks us 
most is that plenty of the “in-active” natural products are 
abundant in plants. So how to make sustainable use of these 
“in-active” natural products becomes a highly valuable project. 
We wonder that if we can turn the “trash” to the “treasure” by 
incorporation of pharmaceutically privileged structure moiety 
through some simple chemical transformations. 
Based on the reasons mentioned above, we would like to 
combine the diverse natural products and the pharmaceutically 
privileged moiety together so as to identify novel drug leads. 
So what moiety will be chosen? The α,β-unsaturated ketone 
moiety came to our sight and became our right choice. 
It is generally believed that Michael acceptors form covalent 
bond with the active site cysteine of the proteases to solicit a 
biological effect8–11. The Cysteine proteases, including papains, 
cathepsins, calpains, caspases and lugumain, represent a 
biologically important clan of protein, which are important 
therapeutic target of tumor, inflammation and auto-immune 
disease12–14. So it is no surprise that Michael acceptors have 
the potential of anti-tumor activity. In 2005, a Michael 
acceptor derived from oleanic acid, TP235, was approved as 
an orphan drug for treatment of pancreatic cancer and also 
used as an agent for treatment of diabetes associated chronic 
kidney disease in late clinical trial15,16. This discovery has 
provoked the keen interests in Michael acceptors. Since then, 
more and more successful examples in drug discovery spring 
up. A cruzain inhibitor, CRA-3386, was approved into clinical 
trial for treatment of Chagas disease17. Another Michael 
acceptor, AG7088, entered into clinical trial Ⅱ for therapy of 
rhinovirus infection18. Schust J. et al. identified a novel 
Michael acceptor, static, as a selective STAT3 activation 
inhibitor from a compound library, and proved that the 
Michael acceptor moiety was its key pharmacophore  
(Figure 1)19. The pioneer work leads us to an idea that 
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identification of novel drug leads from structurally diverse and 
functionally under-mined natural products by introduction 
Michael acceptor moiety. 
With the idea in mind, we then started the execution of the 
plan. Though plenty of methods available in our chemical tool 
box, including Pd(OAc)2 catalyzed Saegusa oxidation20, 
benzeneselenenylation-oxidative elimination sequence21, both 
the methods require trivial operations and relative harsh 
reaction conditions. Fortunately, we have a newly invented 
method namely IBX mediated oxidation available22, which 
features with higher efficiency and simpler operations. The 
power of the method is not fully exemplified, especially in 
complex natural products. 
Herein, we reported the construction of a small diversity-
oriented combinatorial library derived from natural products, 
which featured with α,β-unsaturated carbonyl moiety using 
IBX mediated oxidation. 
 
Results and Discussion 
Starting from structurally diverse natural products, we 
prepared fourteen Michael acceptors efficiently (Table 1). 
All the substrates and the Michael acceptors were evaluated 
on five human tumor cell lines, including HL-60, SMMC-7721, 
A-549, SK-BR-3 and PANC-1, using 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. And 
anticancer drug cisplatin (DDP) was used as the positive 
control (Table 2). 
As summarized in Table 2, four Michael acceptors, 8a, 11a 
and 12a, 14a, are found to be with significantly improved anti-
tumor activity. Especially, compounds 8a and 12a exhibit 
single digit micro-molar inhibitory activity against HL-60, 
SK-BR-3 and PANC-1 cell lines, which are up to 10 times 
more potent than the corresponding parent compounds. It’s 
also pleased to know that the parent compounds 8 and 12 are 
relatively abundant in plants, which are worthy of our further 
attentions. 
Moreover, we also investigated the possible action mode of 
the active hit 8a in a thiol-sensitive assay using an NMR 
method, which was developed by Appendino G. et al23. The 
method was proved effective for identifying Michael acceptors, 
and sorting them into reversible and irreversible thiol sinks. 
Upon treatment of two equivalents of cysteamine, a known 
biologically relevant model thiol24, in deuterated DMSO, a 
Michael adduct of 8b was formed instantaneously (Figure 2), 
and the adduct was irreversible by diluting with CDCl3. The 
results reveal that the Michael acceptor moiety is the key 
pharmacophore of the active hit 8a, and 8a is classified as the 
irreversible Michael acceptor accordingly. 
In conclusion, a potential strategy to identify drug leads and 
re-discover the “trash” natural products is exemplified. The 
possible action mode of typical active hit 8a was also investi-
gated. It was confirmed that the Michael acceptor moiety was 
the key pharmacophore and 8a was an irreversible thiol sink. 
And the superiority of the strategy is apparent, including re-
source saving, increased discovery rate, higher efficiency. 
Optimization process can be furthered based on the leads iden-
tified. Moreover, the strategy also provides an alternative view 
to evaluate the “trash” natural products, and may reward us 
serendipity. 





















Figure 1.  Typical Michael acceptors 
Table 1. Preparation of Michael acceptors 
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Material and Methods. Reagents and solvents were used 
as commercial grade. Toluene and dimethyl sulfoxide (DMSO) 
were treated as anhydrous solvents prior to use. Chroma-
tographies were performed with 300–400 mesh silica gels. 
Thin layer chromatographies were carried out on Merck silica 
plates (0.25 mm layer thickness). ESIMS and HRESIMS were 
taken on a VG Auto Spec-3000 or on a Finnigan MAT 90 
instrument. Optical rotations were measured with a Horiba 
SEPA-300 polarimeter. 1H and 13C NMR experiments were 
performed on a Bruker AM-300, AM-400 and DRX-500 NMR 
spectrometer at ambient temperature. And chemical shifts 
were given in δ with TMS as internal reference. 
 
General Procedure for Preparation of Michael Acceptors
1a–14a16. To a solution of the substrate (1.0 mmol) in 
DMSO/toluene (0.8 mL/0.2 mL) was added IBX (3.0 mmol) in 
one portion. The mixture was heated to 85–95 °C, and was 
followed by TLC until no starting material was detected. Then 
the mixture was cooled to room temperature and diluted with 
H2O. The aqueous layer was extracted with Et2O for three 
times. The combined organic layer was washed with 5%  
NaHCO3 (3 × 10 mL), H2O (1 × 10 mL), and dried (MgSO4), 
followed by removal of solvent in vacuo, leading to crude 
compounds which was purified using flash column  
chromatography on silica gel. 
 
Oleana-1,12-dien-3-oxo-28-oic acid (1a): white foam, 1H 
NMR (500 MHz, CDCl3): δ 7.06 (d, J = 10.1 Hz, 1H), 5.81 (d, 
J = 10.1 Hz, 1H), 5.31 (d, J = 3.7 Hz, 1H), 2.23 (d, J = 11.2 
Hz, 1H), 2.17–2.13 (m, 1H), 2.09 (d, J = 3.9 Hz, 1H), 2.05 (s, 
1H), 2.01 (dd, J = 13.5, 4.2 Hz, 1H), 1.87 (td, J = 13.5, 4.2 Hz, 
1H), 1.80 (dd, J = 11.4, 6.0 Hz, 1H), 1.77–1.72 (m, 1H), 1.68 
(dd, J = 13.2, 3.6 Hz, 2H), 1.59–1.49 (m, 4H), 1.46–1.39 (m, 
2H), 1.38–1.28 (m, 3H), 1.25 (d, J = 2.3 Hz, 1H), 1.21 (dd, J = 
6.4, 2.1 Hz, 1H), 1.17 (s, 3H), 1.14 (s, 3H), 1.10 (s, 3H), 1.07 
(s, 3H), 0.95 (d, J = 6.2 Hz, 2H), 0.86 (s, 3H); 13C NMR (125 
MHz, CDCl3) δ 206.2 (C), 184.6 (C), 160.5 (CH), 139.9 (C), 
126.4 (CH), 55.9 (C), 54.8 (CH), 45.9 (C), 43.7 (C), 43.0 (CH), 
41.6 (C), 40.7 (C), 40.3 (CH), 40.1 (CH), 38.0 (CH2), 34.1 
(CH2), 31.9 (CH2), 29.3 (CH2), 29.2 (CH3), 25.3 (CH2), 24.8 
(CH3), 24.6 (CH2), 22.9 (CH3), 22.4 (CH2), 20.2 (CH2), 20.1 
(CH3), 18.9 (CH3), 18.3 (CH3); HREIMS (m/z): 452.3283 [M]+ 
(calcd for C30H44O3, 452.3290). 
 
Ursa-1,12-dien-3-oxo-28-oic acid (2a): white foam, 1H 
NMR (400 MHz, CDCl3): δ 7.06 (d, J = 10.1 Hz, 1H), 5.81 (d, 
J = 10.1 Hz, 1H), 5.31 (d, J = 3.7 Hz, 1H), 2.23 (d, J = 11.2 
Hz, 1H), 2.17–2.13 (m, 1H), 2.09 (d, J = 3.9 Hz, 1H), 2.05 (s, 
1H), 2.01 (dd, J = 13.5, 4.2 Hz, 1H), 1.87 (td, J = 13.5, 4.2 Hz, 
1H), 1.80 (dd, J = 11.4, 6.0 Hz, 1H), 1.77–1.72 (m, 1H), 1.68 
(dd, J = 13.2, 3.6 Hz, 2H), 1.59–1.49 (m, 4H), 1.46–1.39 (m, 
2H), 1.38–1.28 (m, 3H), 1.25 (d, J = 2.3 Hz, 1H), 1.21 (dd, J = 
6.4, 2.1 Hz, 1H), 1.17 (s, 3H), 1.14 (s, 3H), 1.10 (s, 3H), 1.07 
(s, 3H), 0.95 (d, J = 6.2 Hz, 2H), 0.86 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 205.3 (C), 183.5 (C), 159.2 (CH), 138.5 (C), 
125.0 (CH), 53.3 (CH), 52.6 (CH), 48.0 (C), 44.4 (C), 43.0 
(CH), 42.2 (C), 41.5 (CH), 40.1 (C), 39.3 (C), 38.8 (CH), 38.7 
(CH), 36.5 (CH2), 32.6 (CH2), 30.6 (CH2), 27.8 (CH2), 27.8 
(CH3), 23.9 (CH2), 23.4 (CH3), 23.1 (CH2), 21.5 (CH3), 21.0 
(CH3), 18.7 (CH3), 17.5 (CH3), 16.9 (CH3); HREIMS (m/z): 
452.3291 [M]+ (calcd for C30H44O3, 452.3290). 
 
Lupa-1,12,20(29)-trien-3-one (3a): white foam, 1H NMR 
(400 MHz, CDCl3): δ 7.09 (d, J = 10.2 Hz, 1H), 5.78 (d, J = 
10.2 Hz, 1H), 4.70 (d, J = 1.7 Hz, 1H), 4.58 (s, 1H), 2.39 (td, J 
= 11.0, 5.7 Hz, 1H), 2.04 (s, 1H), 1.97–1.88 (m, 1H), 1.72 (d, 
J = 4.2 Hz, 1H), 1.68 (s, 3H), 1.67–1.59 (m, 2H), 1.58 (s, 1H), 
1.56–1.50 (m, 4H), 1.47 (dt, J = 9.4, 3.9 Hz, 3H), 1.43–1.32 
(m, 5H), 1.24 (d, J = 4.1 Hz, 1H), 1.20 (d, J = 11.0 Hz, 1H), 
1.12 (s, 3H), 1.10 (s, 3H), 1.07 (s, 3H), 1.06 (s, 3H), 1.03–0.99 
(m, 1H), 0.95 (s, 3H), 0.80 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 205.4 (C), 159.8 (CH), 150.6 (C), 125.1 (CH), 109.4 
(CH2), 53.3 (CH), 48.0 (CH), 47.8 (CH), 44.5 (C), 44.3 (CH), 
43.0 (C), 42.9 (C),  41.7 (C), 39.9 (CH2), 39.5 (C), 38.1 (CH), 
35.4 (CH2), 33.7 (CH2), 29.7 (CH2), 27.7 (CH3), 27.3 (CH2), 
25.0 (CH2), 21.3 (CH), 21.1 (CH2), 19.2 (CH), 19.1 (CH3), 
18.9 (CH2), 17.9 (CH3), 16.4 (CH3), 14.3 (CH3); HREIMS 
(m/z): 422.3548 [M]+ (calcd for C30H46O, 422.3549). 
 
Lupa-1,12,20(29)-trien-3-oxo-28-oic acid (4a): white 
foam, 1H NMR (500 MHz, CDCl3): δ 7.11 (d, J = 10.3 Hz, 
1H), 5.80 (d, J = 10.2 Hz, 1H), 4.76 (s, 1H), 4.64 (s, 1H), 3.03 
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(dd, J = 10.7, 6.0 Hz, 1H), 2.34–2.28 (m, 1H), 2.26 (dd, J = 
12.3, 3.2 Hz, 1H), 2.03–1.96 (m, 2H), 1.79 (d, J = 13.2 Hz, 
1H), 1.70 (s, 3H), 1.65 (t, J = 11.4 Hz, 2H), 1.60–1.56 (m, 1H), 
1.56–1.50 (m, 4H), 1.44 (m, 5H), 1.26 (s, 6H), 1.13 (s, 3H), 
1.07 (s, 3H), 1.06 (s, 3H), 1.02 (s, 3H), 1.00 (s, 3H), 0.88 (t, J 
= 6.7 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 205.4 (C), 
181.5 (C), 160.5 (CH), 159.6 (CH), 150.1 (C), 125.1 (CH), 
109.8 (CH2), 56.3 (C), 53.4 (CH), 49.1 (CH), 46.8 (CH ), 44.6 
(C), 44.5 (CH), 42.7(C), 41.6 (C), 39.5 (C), 38.6 (CH), 37.0 
(CH2), 33.8 (CH2), 32.1 (CH2), 30.5 (CH2), 29.6 (CH2), 29.6 
(CH2), 27.7 (CH2), 25.4 (CH2), 21.3 (CH3), 21.1 (CH2), 19.3 
(CH3), 19.1 (CH3), 18.9 (CH2), 16.4 (CH3), 14.5 (CH3); 
HREIMS (m/z): 452.3282 [M]+ (calcd for C30H44O3, 452.3290). 
 
Dammar-1,24(25)-dien-3,12-di-one (5a): white foam, 1H 
NMR (500 MHz, CDCl3): δ 6.94 (d, J = 10.3 Hz, 1H), 5.77 (d, 
J = 10.2 Hz, 1H), 5.04 (s, 1H), 2.85 (d, J = 10.3 Hz, 1H), 2.44 
(dd, J = 14.0, 4.0 Hz, 1H), 2.35 (dt, J = 13.7, 6.6 Hz, 2H), 1.95 
(dd, J = 13.2, 3.9 Hz, 2H), 1.77 (dd, J = 21.8, 11.4 Hz, 1H), 
1.62 (s, 3H), 1.57 (d, J = 2.6 Hz, 1H), 1.55 (s, 3H), 1.41 (d, J 
= 13.4 Hz, 2H), 1.32–1.23 (m, 2H), 1.22 (d, J = 4.1 Hz, 1H), 
1.20 (s, 3H), 1.16 (s, 1H), 1.10 (d, J = 3.1 Hz, 6H), 1.05 (s, 
6H), 1.00 (s, 1H), 0.97 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 
212.0 (C), 204.5 (C), 157.1 (CH), 131.6 (C), 125.8 (CH), 
124.7 (CH), 73.2 (C), 56.4 (CH), 54.8 (C), 53.8 (CH), 47.4 
(CH), 45.7 (CH), 44.7 (C), 41.0 (C), 39.7 (C), 39.0 (CH2), 
38.2 (CH2), 33.4 (CH2), 30.8 (CH2), 27.6 (CH3), 26.4 (CH3), 
25.7 (CH3), 24.5 (CH2), 22.5 (CH2), 21.3 (CH3 ), 19.0 (CH2), 
18.9 (CH3), 17.6 (CH3), 17.3 (CH3), 16.1 (CH3); HREIMS 
(m/z): 454.3453 [M]+ (calcd for C30H46O3, 454.3447). 
 
9,19-Cyclolanost-1,24(25)-dien-3-oxo-26-oic acid (6a): 
white foam, 1H NMR (500 MHz, CDCl3): δ 6.90 (t, J = 7.4 Hz, 
1H), 6.79 (d, J = 10.1 Hz, 1H), 6.73 (s, OH), 5.96 (d, J = 10.0 
Hz, 1H), 2.12 (dd, J = 9.9, 6.0 Hz, 2H), 2.02–1.95 (m, 1H), 
1.90 (dd, J = 12.9, 7.4 Hz, 2H), 1.84 (s, 3H), 1.71–1.49 (m, 
7H), 1.44 (d, J = 9.2 Hz, 1H), 1.36–1.23 (m, 6H), 1.10 (s, 3H), 
0.96 (s, 6H), 0.92 (d, J = 6.4 Hz, 3H), 0.89 (s, 3H), 0.76 (d, J 
= 4.6 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 205.4 (C), 173.3 
(C), 154.1 (CH), 145.6 (CH), 126.6 (CH), 126.6 (C), 51.8 
(CH), 49.1 (C), 45.9 (C), 45.3 (C), 44.2 (CH), 43.5 (CH), 35.9 
(CH), 34.7 (CH2), 34.4 (CH2), 32.2 (CH2), 29.8 (C), 29.1 
(CH2), 27.8 (CH2), 27.7 (CH2), 25.8 (CH2), 24.7 (C), 23.2 
(CH2), 21.3 (CH3), 19.4 (CH2), 19.0 (CH3), 18.4 (CH3), 18.1 
(CH3), 16.8 (CH3), 11.9 (CH3); HREIMS (m/z): 452.3289 [M]+ 
(calcd for C30H44O3, 452.3290). 
 
18-Norpregnane-1-en-3,12,20-tri-one (7a): white foam, 
1H NMR (500 MHz, CDCl3): δ 6.99 (d, J = 10.2 Hz, 1H), 5.82 
(d, J = 10.2 Hz, 1H), 3.22 (td, J = 10.7, 6.9 Hz, 1H), 3.12 (d, J 
= 10.5 Hz, 1H), 2.44 (d, J = 4.4 Hz, 1H), 2.41 (d, J = 13.1 Hz, 
1H), 2.22 (s, 3H), 2.21 (s, 1H), 2.12–2.05 (m, 1H), 1.97 (dd, J 
= 12.8, 4.4 Hz, 1H), 1.83 (dd, J = 20.0, 10.9 Hz, 1H), 1.73–
1.67 (m, 2H), 1.65 (d, J = 2.8 Hz, 2H), 1.61 (d, J = 2.2 Hz, 
1H), 1.47 (d, J = 12.7 Hz, 1H), 1.30 (d, J = 9.8 Hz, 1H), 1.26 
(s, 3H), 1.23 (s, 2H), 1.15 (s, 3H), 1.14 (s, 3H), 1.10 (s, 3H); 
13C NMR (125 MHz, CDCl3) δ 210.4 (C), 208.5 (C), 204.6 (C), 
157.3 (CH), 125.7 (CH), 58.0 (CH), 54.3 (C), 53.7 (CH), 47.2 
(CH), 46.9 (CH), 44.7 (C), 40.9 (C), 39.7 (C), 38.5 (CH2), 
33.6 (CH2), 31.2 (CH2), 30.1 (CH3), 29.6 (CH2), 27.6 (CH3), 
25.6 (CH2), 21.3 (CH3), 18.9 (CH2), 18.9 (CH3), 17.0 (CH3), 
16.0 (CH3); HREIMS (m/z): 370.2516 [M]+ (calcd for 
C24H34O3, 370.2516). 
 
Kaur-16-en-15-oxo-18-oic acid (8a): white foam, 1H NMR 
(500 MHz, CDCl3): δ 5.78 (s, 1H), 5.14 (s, 1H), 2.91 (s, 1H), 
2.28 (d, J = 11.9 Hz, 1H), 2.00 (d, J = 13.1 Hz, 1H), 1.77 (dd, 
J = 11.5, 7.9 Hz, 1H), 1.70 (ddd, J = 23.8, 12.4, 6.8 Hz, 5H), 
1.54 (dd, J = 15.4, 5.8 Hz, 2H), 1.29 (ddd, J = 16.6, 13.1, 6.0 
Hz, 3H), 1.21 (dd, J = 10.3, 3.2 Hz, 1H), 1.08 (s, 3H), 1.03–
0.98 (m, 1H), 0.88 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 
211.6 (C), 180.3 (C), 149.3 (C), 114.7 (CH), 55.8 (CH), 52.4 
(C), 51.5 (CH), 43.2 (C), 40.0 (C), 39.8 (CH2), 37.8 (CH), 
37.6 (CH2), 36.2 (CH2), 33.4 (CH2), 31.8 (CH2), 28.6 (CH3), 
19.8 (CH2), 18.6 (CH2), 18.1 (CH2), 15.2 (CH3); HREIMS 
(m/z): 316.2039 [M]+ (calcd for C20H28O3, 316.2039). 
 
Kaur-16-en-11,15-dioxo-18-oic acid (9a): 1H NMR (500 





HL-60a SMMC-7721b A-549c SK-BR-3d PANC-1e 
1 14.99 14.28 14.75 13.51 14.17 
1a 10.86 26.75 34.05 > 40 > 40 
2 15.23 15.73 16.77 14.93 15.12 
2a 9.25 20.35 34.05 > 40 > 40 
3 > 40 > 40 > 40 > 40 > 40 
3a > 40 > 40 > 40 > 40 > 40 
4 7.62 14.51 11.40 6.80 23.71 
4a 15.23 19.08 34.05 > 40 > 40 
5 14.99 28.99 26.75 16.04 15.25 
5a 15.98 26.32 25.90 18.53 18.68 
6 > 40 > 40 > 40 > 40 > 40 
6a > 40 > 40 > 40 > 40 > 40 
7 > 40 > 40 > 40 > 40 > 40 
7a > 40 > 40 > 40 > 40 > 40 
8 > 40 > 40 > 40 > 40 > 40 
8a 6.39 6.59 12.76 14.46 17.58 
9 > 40 > 40 > 40 > 40 > 40 
9a > 40 > 40 > 40 > 40 > 40 
10 > 40 > 40 > 40 > 40 > 40 
10a > 40 > 40 > 40 > 40 > 40 
11 > 40 > 40 > 40 > 40 > 40 
11a 14.99 21.35 > 40 18.05 19.80 
12 > 40 > 40 > 40 > 40 > 40 
12a 6.59 10.18 12.16 4.92 3.76 
13 > 40 > 40 > 40 > 40 > 40 
13a > 40 > 40 > 40 > 40 > 40 
14 > 40 > 40 > 40 > 40 > 40 
14a 12.55 14.05 16.51 13.63 12.13 
DDPf 1.94 14.99 13.39 15.68 25.57 
aHL-60, Human promyelocytic leukemia cell line; bSMMC-7721, 
human hepatocellular carcinoma cell line; cA-549, Human lung 
carcinoma cell line; dSK-BR-3, Human breast adenocarcinoma 
cell line; ePANC-1, Human pancreatic carcinoma, epithelial-like 
cell line; hDDP: cisplatin, which was used as the positive control. 
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MHz, MeOD) δ 6.03 (s, 1H), 5.42 (s, 1H), 3.28 (s, 1H), 2.82 
(d, J = 12.5 Hz, 1H), 2.65 (dd, J = 12.1, 4.0 Hz, 1H), 2.57 (d, J 
= 15.9 Hz, 1H), 2.20 (d, J = 9.6 Hz, 1H), 2.02 (m, 1H), 1.97 (d, 
J = 14.0 Hz, 1H), 1.92 (s, 1H), 1.89 (d, J = 3.6 Hz, 1H), 1.88 
(s, 1H), 1.80 (d, J = 13.9 Hz, 1H), 1.70–1.76 (m, 2H), 1.59 (d, 
J = 10.2 Hz, 1H), 1.48 (d, J = 14.7 Hz, 1H), 1.29 (s, 3H), 1.23 
(s, 1H), 1.20 (dd, J = 13.6, 4.3 Hz, 1H), 1.09 (dd, J = 13.5, 4.1 
Hz, 1H), 1.02 (s, 3H), 0.88 (m, 1H); 13C NMR (125 MHz, 
CDCl3) δ 209.1 (C), 206.5 (C), 183.4 (C), 147.4 (C), 118.5 
(CH2), 67.0 (CH), 55.4 (CH), 52.64 (C), 51.4 (CH2), 43.8 (C), 
40.0 (C), 37.4 (CH2), 36.5 (CH), 35.8 (CH2), 32.0 (CH2), 29.6 
(CH2), 28.8 (CH3), 19.8 (CH2), 18.5 (CH2), 17.1 (CH3); 
HREIMS (m/z): 330.1833 [M]+ (calcd for C20H26O4, 330.1831). 
 
Labda-1,11-dien-3-oxo-13-oic acid (10a): white foam, 1H 
NMR (500 MHz, CDCl3): δ 7.10 (d, J = 10.4 Hz, 1H), 5.97 (d, 
J = 10.4 Hz, 1H), 5.71 (s, 1H), 5.03 (s, 1H), 4.69 (s, 1H), 2.51 
(d, J = 13.0 Hz, 1H), 2.21 (s, 3H), 2.17 (s, 1H), 1.90 (dd, J = 
20.1, 6.9 Hz, 2H), 1.73 (ddd, J = 17.8, 15.0, 8.4 Hz, 2H), 1.53 
(dd, J = 13.0, 3.9 Hz, 1H), 1.16 (s, 3H), 1.06 (s, 3H), 0.92 (s, 
3H).; 13C NMR (125 MHz, CDCl3) δ 204.6 (C), 171.4 (C), 
162.6 (C), 155.7 (CH), 146.0 (C), 126.9 (CH), 115.1 (CH), 
109.3 (CH2), 52.3 (CH), 51.3 (CH), 44.7 (C), 29. 6 (C), 27.0 
(CH3), 24.0 (CH2), 22.0 (CH2), 21.8 (CH3), 19.2 (CH3), 16.3 
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Figure 2.  Reaction of compound 9a with cysteamine. A) 1H NMR spectrum of 9a in [D6]-DMSO; B) Spectrum recorded 5 min 
after the addition of 2 mol equiv cysteamine; C) Spectrum recorded 5 min after dilution (1:20) of the reaction mixture with CDCl3. 
All spectra were taken at 400 MHz. Note the complete and irreversible disappearance of the olefin signals at d= 5.49 and 5.41 ppm 
(H-17a and H-17b) upon addition of cysteamine. 
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29. 6 (C), 27.0 (CH3), 24.0 (CH2), 22.8 (CH2), 21.7 (CH3), 
16.4 (CH3); HREIMS (m/z): 434.3173 [M]+ (calcd for 
C30H42O2, 434.3173). 
 
Stigmasta-1,5-dien-3-one (13a): white foam, 1H NMR 
(400 MHz, CDCl3): δ 6.15 (d, J = 11.0 Hz, 1H), 6.09 (dd, J = 
9.8, 2.4 Hz, 1H), 5.67 (s, 1H), 2.60–2.55 (m, 1H), 2.54 (d, J = 
5.3 Hz, 1H), 2.45 (d, J = 3.7 Hz, 1H), 2.41 (d, J = 5.6 Hz, 1H), 
2.19 (t, J = 10.3 Hz, 1H), 2.08 (d, J = 3.2 Hz, 1H), 2.06–2.03 
(m, 1H), 2.03–1.97 (m, 1H), 1.95–1.87 (m, 1H), 1.73–1.69 (m, 
1H), 1.69–1.65 (m, 1H), 1.61 (s, 3H), 1.55–1.50 (m, 1H), 1.45 
(d, J = 3.7 Hz, 1H), 1.40 (dd, J = 13.0, 3.7 Hz, 2H), 1.34 (d, J 
= 12.8 Hz, 2H), 1.30 (d, J = 7.7 Hz, 2H), 1.27–1.13 (m, 12H), 
1.11 (s, 3H), 1.05–0.99 (m, 2H), 0.94 (t, J = 6.3 Hz, 3H), 0.87 
(s, 3H), 0.85 (s, 3H), 0.83 (d, J = 2.3 Hz, 3H), 0.81 (d, J = 2.7 
Hz, 3H), 0.76 (d, J = 4.6 Hz, 3H), 0.71 (s, 1H); 13C NMR (100 
MHz, CDCl3) δ 199.7 (C), 164.0 (C), 141.6 (CH), 127.7 (CH), 
123.4 (CH), 55.8 (CH), 53.3 (CH), 50.6 (CH), 45.7 (CH), 43.3 
(C), 39.4 (CH2), 37.7 (CH), 36.1 (CH), 33.9 (CH2), 33.8 (CH2), 
33.8 (CH2), 29.0 (CH), 28.1 (CH2), 26.0 (CH2), 23.6 (CH2), 
23.0 (CH2), 20.6 (CH2), 19.7 (CH3 ), 18.9 (CH3), 18.6 (CH3 ), 
16.2 (CH3), 11.9 (CH3 ), 11.8 (CH3); HREIMS (m/z): 410.3546 
[M]+ (calcd for C29H46O, 410.3549). 
 
Stigmasta-4-methyl-1,7(8),24(28)-triene-3,6,23-tri-one (14a):
white foam, 1H NMR (400 MHz, CDCl3): δ 6.15 (d, J = 11.0 
Hz, 1H), 6.09 (dd, J = 9.8, 2.4 Hz, 1H), 5.67 (s, 1H), 2.60–
2.55 (m, 1H), 2.54 (d, J = 5.3 Hz, 1H), 2.45 (d, J = 3.7 Hz, 
1H), 2.41 (d, J = 5.6 Hz, 1H), 2.19 (t, J = 10.3 Hz, 1H), 2.08 
(d, J = 3.2 Hz, 1H), 2.06–2.03 (m, 1H), 2.03–1.97 (m, 1H), 
1.95–1.87 (m, 1H), 1.73–1.69 (m, 1H), 1.69–1.65 (m, 1H), 
1.61 (s, 3H), 1.55–1.50 (m, 1H), 1.45 (d, J = 3.7 Hz, 1H), 1.40 
(dd, J = 13.0, 3.7 Hz, 2H), 1.34 (d, J = 12.8 Hz, 2H), 1.30 (d, J 
= 7.7 Hz, 2H), 1.27–1.13 (m, 12H), 1.11 (s, 3H), 1.05–0.99 (m, 
2H), 0.94 (t, J = 6.3 Hz, 3H), 0.87 (s, 3H), 0.85 (s, 3H), 0.83 
(d, J = 2.3 Hz, 3H), 0.81 (d, J = 2.7 Hz, 3H), 0.76 (d, J = 4.6 
Hz, 3H), 0.71 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 202.7 
(C), 200.7 (C), 198.1 (C), 160.4 (C), 152.2 (CH), 148.5 (C), 
135.1 (CH), 127.3 (CH), 123.8 (CH), 55.8 (CH), 53.3 (CH), 
50.6 (CH), 45.7 (CH), 43.3 (C), 39.4 (CH2), 37.7 (CH), 36.1 
(CH), 33.9 (CH2), 33.8 (CH2), 33.8 (CH2), 29.0 (CH), 28.1 
(CH2), 26.0 (CH2), 23.6 (CH2), 23.0 (CH2), 20.6 (CH2), 19.7 
(CH3), 18.9 (CH3), 18.6 (CH3), 16.2 (CH3), 11.9 (CH3), 11.8 
(CH3); HREIMS (m/z): 450.3136 [M]+ (calcd for C30H42O3, 
450.3134). 
 
Thiol Sensitive Assay. Compound 8a (10 mg, 0.03 mmol) 
was dissolved in d6-DMSO (500 μL) in a 5 mm NMR tube, 
and the spectrum was recorded (Figure 2A). Cysteamine (4.7 
mg, 0.06 mmol, 2 mol equiv) was then added, and the  
spectrum was recorded 5 min after the addition (Figure 2B). 
An aliquot (25 μL) of the solution was then transferred into a 
second NMR tube containing CDCl3 (500 μL) and a new  
spectrum was recorded (Figure 2C). A positive result was  
evidenced by the disappearance of a particular olefin system of 
the substrate, and the irreversibility of the Michael addition by 
its disappearance upon dilution 1:20 with CDCl3. 
 
Biological Assay. The used cell lines were human promye-
locytic leukemia cell line (HL-60), human hepatocellular  
carcinoma cell line (SK-BR-3), human lung carcinoma cell 
line (A-549), human breast adenocarcinoma cell line (SMMC-
7721), human pancreatic carcinoma cell line (PANC-1). An 
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] colorimetric assay was performed in 96-well plates. 
HL-60 cells at the log phase of their growth cycle (1.25 × 105 
cell/mL) were added to each well (90 mL/well), then treated in 
four replicates at various concentrations of the samples (1–100 
µg/mL), and incubated for 48 hours at 37 °C in a humidified 
atmosphere of 5% CO2. After 48 h, 10 µL of MTT solution (5 
mg/mL) per well was added to each cultured medium, which 
were incubated for further 4 hours. Then, a three-system  
solution of 10% SDS–5% isobutanole–0.012 mol/L hydrochlo-
ric acid was added to each well (100 µL/well). After 12 h at 
room temperature, the OD of each well was measured on a 
Microplate Reader (BIO-TEK instruments Inc EL311S) at a 
wavelength of 570 nm. In these experiments, the negative  
reference agents was 0.1% DMSO, and cisplatin (DDP) was 
used as the positive control with concentration of 1–80 µg/mL. 
The same method was used in cytotoxic testing against SK-
BR-3, A549, SMMC-7721 and PANC-1 cell lines. 
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